ts-108
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2004 (NCT00166543)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptor alphaANTAGONIST
ESR1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCN(CC)Cc1ccc(OCC[C@H]2CCC3C4C(CC[C@@]32C)c2ccc(O)cc2C[C@H]4C)c(OC)c1- Mol. weight
- 505.74 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545211 ↗
- ChEMBLCHEMBL3545210 ↗
Also known as
- sr16234
- sr16234
- sr16234
- sr 16234
- sr-16234
- sr-16234
- sr-16234
- tas108
- tas-108
- tas-108
- tas-108
- ts 108
- ts-108
- ts-108
- ts-108
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00166543 | Phase 2 | May 1, 2004 | Mayo Clinic, Otsuka, SRI International |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Otsuka | For profit | 1 | 0 | 1 | 2004 |
| SRI International | Academic/Hospital | 1 | 1 | 1 | 2004 |
3 organizations
Page 1 / 1